Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Series D Preferred Stock	Series E Preferred Stock	At the market offering	Private placement	Preferred shares	Preferred shares Series D Preferred Stock	Preferred shares Series E Preferred Stock	Common shares	Common shares Series D Preferred Stock	Common shares Series E Preferred Stock	Common shares At the market offering	Common shares Private placement	Additional paid-in capital	Additional paid-in capital Series D Preferred Stock	Additional paid-in capital Series E Preferred Stock	Additional paid-in capital At the market offering	Additional paid-in capital Private placement	Accumulated other comprehensive loss	Accumulated deficit
Balance at beginning of period (shares) at Dec. 31, 2019						11			55,212
Balance at beginning of period at Dec. 31, 2019	$ 51,352					$ 0			$ 55					$ 227,468					$ (1,995)	$ (174,176)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,547)																			(8,547)
Foreign currency translation adjustment	830																		830	0
Unrealized gain on investments	101																		101
Stock based compensation expense	2,520													2,520					0
Issuance of common stock resulting from exercise of stock options (in shares)									139
Issuance of common stock resulting from exercise of stock options	271													271
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)									47
Issuance of common stock resulting from purchase of employee stock purchase plan shares	145													145
Preferred stock conversion (shares)							3			3,000
Preferred stock conversion value		$ 0								$ (3)					$ 3
Balance at end of period (shares) at Jun. 30, 2020						14			52,399
Balance at end of period at Jun. 30, 2020	46,672					$ 0			$ 52					230,407					(1,064)	(182,723)
Balance at beginning of period (shares) at Mar. 31, 2020						11			55,212
Balance at beginning of period at Mar. 31, 2020	49,806					$ 0			$ 55					228,751					(1,227)	(177,773)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,950)																			(4,950)
Foreign currency translation adjustment	178																		178
Unrealized gain on investments	(15)																		(15)
Stock based compensation expense	1,237													1,237
Issuance of common stock resulting from exercise of stock options (in shares)									139
Issuance of common stock resulting from exercise of stock options	271													271
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)									47
Issuance of common stock resulting from purchase of employee stock purchase plan shares	145													145
Preferred stock conversion (shares)							3			3,000
Preferred stock conversion value		$ 0								$ (3)					$ 3
Balance at end of period (shares) at Jun. 30, 2020						14			52,399
Balance at end of period at Jun. 30, 2020	46,672					$ 0			$ 52					230,407					(1,064)	(182,723)
Balance at beginning of period (shares) at Dec. 31, 2020						14			56,003
Balance at beginning of period at Dec. 31, 2020	31,027					$ 0			$ 56					242,672					(295)	(211,406)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,670)																			(19,670)
Foreign currency translation adjustment	529																		529
Stock based compensation expense	2,525													2,525
Issuance of common stock resulting from exercise of stock options (in shares)									139
Issuance of common stock resulting from exercise of stock options	292													292
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)									40
Issuance of common stock resulting from purchase of employee stock purchase plan shares	96													96
Issuance of common stock resulting from exercise of warrants (in shares)									1,391
Issuance of common stock resulting from exercise of warrants	837								$ 1					836
Preferred stock conversion (shares)						4		5	3,812		5,000
Preferred stock conversion value	0		$ 0						$ 4		$ (5)			(4)		$ 5
Issuance of common stock pursuant to offering (in shares)												3,004	7,290
Issuance of common stock pursuant to offering value				$ 12,172	$ 18,913							$ 3	$ 8				$ 12,169	$ 18,905
Balance at end of period (shares) at Jun. 30, 2021						16			66,679
Balance at end of period at Jun. 30, 2021	46,721					$ 0			$ 67					277,496					234	(231,076)
Balance at beginning of period (shares) at Mar. 31, 2021						14			59,719
Balance at beginning of period at Mar. 31, 2021	38,236					$ 0			$ 60					253,560					194	(215,578)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(15,498)																			(15,498)
Foreign currency translation adjustment	40																		40
Stock based compensation expense	1,326													1,326
Issuance of common stock resulting from exercise of stock options (in shares)									129
Issuance of common stock resulting from exercise of stock options	272													272
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)									40
Issuance of common stock resulting from purchase of employee stock purchase plan shares	96													96
Issuance of common stock resulting from exercise of warrants (in shares)									1,391
Issuance of common stock resulting from exercise of warrants	837								$ 1					836
Preferred stock conversion (shares)						4		5	3,812		5,000
Preferred stock conversion value	0		$ 0						$ 4		$ (5)			(4)		$ 5
Issuance of common stock pursuant to offering (in shares)												3,004	3,584
Issuance of common stock pursuant to offering value				$ 12,172	$ 9,240							$ 3	$ 4				$ 12,169	$ 9,236
Balance at end of period (shares) at Jun. 30, 2021						16			66,679
Balance at end of period at Jun. 30, 2021	$ 46,721					$ 0			$ 67					$ 277,496					$ 234	$ (231,076)